Patients receiving semaglutide (0.5 or 1.0 mg) for 104 weeks demonstrated a significantly higher risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or required procedural treatment compared to those receiving placebo (HR, 1.76
MEDICAL REFERENCE: GLP and FIBROMYALGIA
In some trial data, lean mass loss has exceeded what clinicians expected at higher doses and faster weight loss rates
-Patients taking Wegovy had an average weight loss of 14.9% after 68 weeks 1 -Patients who took Saxenda had between 5 and 10% weight loss compared with placebo after 56 weeks 2 Medically supervised weight management with GLP-1 prescriptions or refills available online Most GLP-1 side effects are associated with mild abdominal discomfort
Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al